GLP-1 on Medicare Part D in 2026: Coverage Changes

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Wegovy® has a list price of about $1,350 per month for both the weekly injection pen and the daily pill.
Without insurance, cash-pay prices for the Wegovy® injection pen are estimated to be $199-$349 per month through NovoNordisk's NovoCare Pharmacy.
Insurance coverage can bring the monthly cost for Wegovy® down to $25-$150, depending on the plan.
New uninsured and self-pay patients can pay $25 per month for the first two months of Ozempic® 0.25 mg or 0.5 mg, as part of a limited-time offer.

Understanding the costs and coverage for GLP-1 medications like Wegovy® and Ozempic® in 2026 is important, especially with ongoing changes in drug pricing and insurance policies. Wegovy® has a list price of about $1,350 per month, whether it's the weekly injection pen or the new daily pill approved in late 2025. However, what people actually pay can vary greatly. Without insurance, cash-pay prices through NovoNordisk’s NovoCare Pharmacy might range from $199 to $349 per month for the injection pen, and $149 to $299 for the pill. For those with insurance, the monthly cost for Wegovy® could fall between $25 and $150, depending on their specific plan and coverage details. Wegovy Cost Without Insurance in 2026 provides further insight into these shifting prices.

What are GLP-1 Medications and Their Uses?

GLP-1 medications are a class of drugs, including semaglutide, that are used effectively for managing weight and treating type 2 diabetes. These medications work by mimicking a natural hormone in the body, which helps regulate blood sugar and appetite.

Wegovy®, a semaglutide medication, is known for its effectiveness in managing weight. It is available as a weekly injection pen and a daily pill. Ozempic®, another semaglutide injection, is primarily used for individuals with type 2 diabetes. While these medications offer significant benefits, it is crucial to understand that Wegovy® may cause serious side effects, including the possibility of thyroid tumors, which could include cancer. These potential risks were observed in studies with rodents, where Wegovy® and similar medicines caused thyroid tumors, including thyroid cancer. However, it is not yet known if Wegovy® will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.

Important Safety Information for Wegovy®

Before starting Wegovy®, it is vital to discuss your full medical history with your healthcare provider. There are specific conditions that would prevent someone from using Wegovy®. For example, if you or any member of your family has ever had medullary thyroid carcinoma (MTC), or if you have an endocrine system condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), you should not use Wegovy®. Additionally, individuals who have had a serious allergic reaction to semaglutide or any other ingredients in Wegovy® injection or tablets should avoid its use. Symptoms of a serious allergic reaction can include swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting, or feeling dizzy.

Patients should also inform their healthcare provider if they have or have had problems with their pancreas or kidneys. Those with type 2 diabetes and a history of diabetic retinopathy need to be particularly cautious. If you are scheduled for surgery or other procedures requiring anesthesia or deep sedation, your healthcare provider should be aware of your Wegovy® use. For women, it is important to know that Wegovy® may harm an unborn baby. Therefore, you should stop using Wegovy® two months before you plan to become pregnant. Breastfeeding is not recommended during treatment with Wegovy® tablets, and it is unknown if the injected form of Wegovy® passes into breast milk.

Potential Side Effects and Drug Interactions

Beyond thyroid concerns, Wegovy® can cause other serious side effects. One such side effect is inflammation of your pancreas, known as pancreatitis. If you experience severe pain in your stomach area that does not go away, with or without nausea or vomiting, you should stop using Wegovy® and call your healthcare provider right away. This pain can sometimes spread from your abdomen to your back. Gallbladder problems, including gallstones, are another possible side effect. Some gallstones may even require surgery. Symptoms to watch for include pain in your upper stomach, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools. If these symptoms appear, contact your healthcare provider.

It is also crucial to tell your healthcare provider about all medicines you are taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements. Wegovy® can affect how some medicines work, and some medicines can affect how Wegovy® works. This is especially true if you are taking other medicines to treat diabetes, such as sulfonylureas or insulin. Wegovy® slows down stomach emptying, which can impact medicines that need to pass through the stomach quickly. This interaction can change how effectively other medications work in your body. Being transparent with your healthcare provider about all medications is essential for your safety and the effectiveness of your treatment plan.

What is the Cost of Wegovy® in 2026?

The cost of Wegovy® in 2026 varies significantly based on insurance coverage and whether the medication is the injection pen or the newly approved daily pill. The list price for Wegovy® stands at about $1,350 per month for both the weekly injection pen and the daily pill.

However, the amount people actually pay without insurance has seen shifts due to various factors, including government regulations, manufacturer programs, and how pharmacies handle cash-pay prescriptions. "While Wegovy® has a list price of $1,350, what people can expect to pay without insurance has shifted over time due to government rule and regulation changes, manufacturer programs, and how pharmacies handle cash-pay prescriptions," according to the Noom Blog. This means that while the sticker price is high, there are other avenues that can lead to lower out-of-pocket expenses.

Retail and Cash-Pay Prices

For individuals paying out-of-pocket without insurance, the estimated monthly prices for Wegovy® are considerably lower than the list price. Through NovoNordisk’s NovoCare Pharmacy, the cash-pay price for the Wegovy® injection pen typically ranges from $199 to $349 per month. The Wegovy® pill, which received approval in late 2025, offers a slightly different price range for cash-pay patients, estimated at $149 to $299 per month. These figures represent a substantial reduction from the list price, showing the impact of manufacturer programs and direct pharmacy arrangements. The retail price of Wegovy® is $1,349, but even without insurance, various programs aim to bring this down.

Several factors influence the final price you will pay for Wegovy®. These include your specific treatment plan, the type of insurance coverage you have (or lack thereof), the pharmacy you choose to fill your prescription, and whether you qualify for any of the available Wegovy® savings programs. It is always recommended to speak with your doctor, pharmacist, or insurance provider to get an accurate estimate of what your personal cost will be. Because drug pricing, manufacturer programs, and insurance coverage continue to shift, it’s worth staying informed before deciding whether Wegovy® fits your budget, as noted by the Noom Blog. This emphasizes the dynamic nature of medication costs and the importance of staying updated on the latest information.

Insurance Coverage and Cost Reductions

For those with insurance, the monthly cost for Wegovy® can be significantly lower. With insurance, the estimated monthly price for both the injection pen and the pill can range from $25 to $150. This wide range depends heavily on your specific insurance plan and the level of coverage it provides for weight-loss medications. While some insurance plans are beginning to cover weight-loss medications, many still do not, which means patients might still pay out of pocket even with insurance. This is a crucial point for anyone considering Wegovy® for weight loss, as insurance acceptance for this specific use is still evolving.

It is important to understand your insurance benefits thoroughly. Some plans may require a prior authorization for GLP-1 medications, which can add a layer of complexity to accessing the drug. Even with insurance, co-pays, deductibles, and formulary restrictions can influence the final cost. Patients should directly contact their insurance provider to understand their specific coverage for Wegovy® and any associated out-of-pocket expenses. This proactive approach can help you budget accurately and avoid unexpected costs. Understanding these different cost scenarios is key to making an informed decision about integrating Wegovy® into your health regimen, especially given the continuous changes in drug pricing and coverage.

How Can You Save on Wegovy® Costs?

Saving on the cost of Wegovy® is possible through several avenues, including manufacturer programs, direct pharmacy partnerships, and prescription discount websites. Given the list price of approximately $1,350 per month, these savings opportunities can significantly reduce the financial burden for many patients.

One primary way to save is through NovoNordisk’s NovoCare Pharmacy program. This program is designed to provide more affordable cash-pay options for patients without insurance or whose plans do not cover weight-loss medications. Through this program, the cash-pay prices without insurance for the Wegovy® injection pen are estimated to be between $199 and $349 per month. For the new Wegovy® pill, approved in late 2025, the cash-pay prices are estimated to be $149 to $299 per month. These prices are substantially lower than the retail list price, highlighting the benefit of utilizing manufacturer-supported programs.

Manufacturer Savings and Subscription Plans

The manufacturer of Wegovy® has actively worked to make the medication more accessible by launching lower-cost subscription plans. These plans are part of a broader effort to address the high cost of GLP-1 medications and improve patient access. While specific details of these subscription plans were not fully outlined in the research, their existence indicates a commitment from the manufacturer to provide more affordable options. Patients interested in these plans should inquire with their healthcare provider or directly with NovoNordisk for the most current information. These initiatives demonstrate a response to the ongoing concerns about the expense of these effective treatments.

Additionally, patients may qualify for the Wegovy® savings program. This program is designed to help reduce out-of-pocket costs for eligible patients. Eligibility criteria typically involve having commercial insurance and meeting certain income requirements. The savings program can offer significant reductions in co-pays, making the medication more affordable for those with insurance. To find out if you qualify for the Wegovy® savings program, it is best to visit the official Wegovy® website or speak with your healthcare provider or pharmacist, who can guide you through the application process. Utilizing such programs can be a crucial step in managing the long-term cost of treatment. Wegovy® Cost and Coverage Information can provide more details on these savings opportunities.

Prescription Discount Websites and Coupons

Another effective way to save on Wegovy® costs is by using prescription discount websites and coupons. These websites can offer coupons that reduce the cost of your medication. For example, some sources indicate that you may be able to save up to $55 per fill off the retail price of Wegovy® by using these coupons. These discount coupons cannot be combined with insurance copays or benefits. However, the discounted price offered through these programs may sometimes be lower than what you would pay through your insurance, especially if your plan has a high deductible or limited coverage for weight-loss medications.

When considering using prescription discount coupons, it is important to compare the discounted price with your insurance co-pay or out-of-pocket cost. This comparison will help you determine the most cost-effective option for you. The cost of prescription medications, such as Wegovy®, is typically higher without insurance than with insurance. However, Wegovy® costs can also depend on other factors, such as the specific pharmacy you use. Different pharmacies may have different pricing agreements with discount card providers, so it may be beneficial to shop around. By exploring all these avenues—manufacturer programs, savings cards, and discount coupons—patients can significantly reduce their financial burden and improve their access to Wegovy®.

What Are the Important Safety Considerations for Wegovy®?

Wegovy® comes with important safety considerations that patients and healthcare providers must be aware of before starting treatment. The most significant concern highlighted is the potential for thyroid tumors, including cancer.

Studies conducted in rodents showed that Wegovy® and other medications that work similarly caused thyroid tumors, including thyroid cancer. While it is not yet known if Wegovy® will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans, this risk is serious enough to warrant specific warnings. Patients are advised to tell their healthcare provider if they experience symptoms such as a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath, as these could be signs of thyroid cancer. This information is critical for anyone considering or currently using Wegovy®.

Contraindications and Pre-existing Conditions

There are clear contraindications for using Wegovy®. You should not use Wegovy® if you or any of your family members have a history of medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These conditions significantly increase the risk of thyroid cancer, making Wegovy® unsafe for these individuals. Additionally, a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® injection or tablets is another reason to avoid the medication. Symptoms of such a reaction can be severe and require immediate medical attention.

Before starting Wegovy®, it is essential to inform your healthcare provider about all your medical conditions. This includes any past or current problems with your pancreas or kidneys. Patients with type 2 diabetes who also have a history of diabetic retinopathy need to exercise caution and discuss this thoroughly with their doctor, as Wegovy® may impact this condition. If you are scheduled for surgery or any other procedure that involves anesthesia or deep sedation, your healthcare provider needs to be aware of your Wegovy® use, as it may affect how other medications interact with your body during these procedures. Open and honest communication with your medical team is paramount for your safety while on Wegovy®.

Pregnancy, Breastfeeding, and Drug Interactions

For women, specific considerations apply regarding pregnancy and breastfeeding. Wegovy® may harm an unborn baby. Therefore, if you are pregnant or planning to become pregnant, you should stop using Wegovy® at least two months before you intend to conceive. This precaution is vital to minimize any potential risks to the developing fetus. Breastfeeding is not recommended during treatment with Wegovy® tablets, and it is currently unknown whether the injected form of Wegovy® passes into breast milk. If you are breastfeeding or plan to breastfeed, discuss the risks and benefits with your healthcare provider to make an informed decision.

Furthermore, informing your healthcare provider about all medicines you take is crucial. This includes prescription and over-the-counter medications, vitamins, and herbal supplements. Wegovy® can affect the way some medicines work, and conversely, some medicines can affect how Wegovy® works. This is particularly important if you are taking other medications for diabetes, such as sulfonylureas or insulin. Wegovy® is known to slow stomach emptying, which can significantly alter the absorption and effectiveness of medicines that need to pass through the stomach quickly. Failing to disclose all medications could lead to dangerous interactions or reduced effectiveness of your treatments. Always provide a complete and accurate list of all your medications to your healthcare provider to ensure safe and effective treatment with Wegovy®. Wegovy® Cost and Coverage Information contains comprehensive safety information for patients.

How Do Prior Authorizations Affect GLP-1 Access?

Prior authorizations significantly affect access to GLP-1 medications, often creating a barrier that patients must navigate before their insurance will cover the cost. This administrative step requires healthcare providers to obtain approval from an insurance company before a patient can fill a prescription for certain drugs, including many GLP-1s.

The process of prior authorization involves submitting detailed clinical information to the insurer, justifying the medical necessity of the prescribed GLP-1 medication. This can be a time-consuming and complex process, often requiring extensive documentation from the prescribing doctor. For patients, this means a delay in starting treatment, and sometimes, outright denial of coverage if the strict criteria set by the insurance company are not met. The complexity of these requirements can be a major challenge for both patients and healthcare providers, impacting timely access to these effective medications. These challenges are a known issue in the healthcare landscape, as discussed in articles like "Navigating GLP-1 Medications: Prior Authorization Challenges and Solutions" from Pharmacy Times.

Challenges in the Prior Authorization Process

Navigating prior authorization for GLP-1 medications presents several challenges. One major hurdle is the sheer volume of paperwork and the specific clinical details required by insurance companies. Providers must often document a patient's diagnosis, previous treatments, body mass index (BMI), comorbidities, and reasons why alternative treatments are not suitable. This can be particularly burdensome for clinics and individual practitioners, diverting resources from direct patient care to administrative tasks. The criteria for approval can also vary widely between different insurance plans, making it difficult for providers to keep up with all the specific requirements.

Another challenge is the potential for delays. The review process can take days or even weeks, during which the patient's condition may worsen or they may become discouraged. If the initial request is denied, an appeals process often follows, which adds further delays and administrative burden. These delays can be frustrating for patients who are eager to start treatment for weight management or diabetes control. For some, the difficulty of obtaining prior authorization might even lead them to abandon treatment altogether, hindering their health outcomes. Simplifying these processes is crucial for improving patient access to GLP-1 medications.

Solutions to Simplify Prior Authorization

Fortunately, solutions are emerging to help simplify the GLP-1 prior authorization process. Technology plays a significant role in streamlining these administrative tasks. Electronic prior authorization (ePA) systems allow healthcare providers to submit requests and supporting documentation electronically, which can speed up the submission and review process. These systems can also integrate with electronic health records (EHRs), making it easier to pull necessary patient information for the authorization request. This reduces manual errors and improves efficiency.

One notable resource for simplifying GLP-1 prior authorization is the CoverMyMeds web page. This platform helps providers manage prior authorizations for a wide range of medications, including GLP-1s. By centralizing the process and offering tools to guide providers through the specific requirements of different insurance plans, CoverMyMeds aims to reduce the time and effort involved. Such platforms can help ensure that all necessary information is submitted correctly the first time, increasing the likelihood of approval and reducing delays. By leveraging these technological solutions and standardized processes, healthcare providers can more effectively navigate the complexities of prior authorization, ultimately improving patient access to GLP-1 medications and ensuring they receive the care they need.

How Does Ozempic® Compare in Terms of Savings?

Ozempic® also offers various savings programs, especially for those with commercial insurance or who are uninsured and self-pay. These programs aim to make the medication more affordable, similar to the efforts seen with Wegovy®.

For commercially covered patients, Ozempic® provides significant savings. Eligible patients can pay as little as $25 for up to a 3-month prescription of any dose of Ozempic®. This is a substantial reduction from the full cost and makes the medication much more accessible for those with commercial insurance plans. This type of savings card or program is a common strategy by pharmaceutical manufacturers to help patients manage their out-of-pocket expenses, particularly for long-term treatments like those for type 2 diabetes. The program's structure allows patients to receive a significant supply of the medication at a low cost, which helps with adherence and consistent treatment.

Savings for Uninsured and Self-Pay Patients

Ozempic® also extends savings opportunities to uninsured and self-pay patients, albeit with some specific conditions. As part of a limited-time offer, new uninsured and self-pay patients can pay $25 per month for the first two months of Ozempic® 0.25 mg or 0.5 mg. This introductory offer helps new patients start their treatment at a significantly reduced cost, allowing them to experience the benefits of the medication without a high initial financial burden. This approach is particularly helpful for those who are just beginning their treatment journey and need to assess the medication's effectiveness and tolerability.

For existing uninsured and self-pay patients, different pricing structures are available for various doses of Ozempic®. While the research does not specify the exact amounts for existing patients at all doses, it indicates that specific pricing exists for Ozempic® 0.25 mg, 0.5 mg, or 1 mg, and a separate pricing structure for Ozempic® 2 mg. This tiered approach likely aims to provide continued support to patients who have been on the medication for some time. Patients in this category should consult the official Ozempic® savings and resources page or speak with their pharmacist to understand their specific eligibility and the exact costs for their prescribed dose.

Accessing Ozempic® Savings and Support

To take advantage of these savings, patients typically need to enroll in the Ozempic® Savings Card program. This involves meeting specific eligibility criteria, which usually include not being enrolled in government healthcare programs like Medicare or Medicaid. The program is designed for commercially insured patients or those paying cash, ensuring that the benefits are directed to the intended demographic. The availability of these savings programs can be a deciding factor for many patients when choosing a GLP-1 medication for type 2 diabetes.

The Ozempic® Savings Card information page provides comprehensive details on how to enroll and the terms and conditions of the offers. It's crucial for patients to review these details carefully to ensure they meet all requirements. By offering multiple ways to save, Ozempic® aims to improve adherence and long-term management of type 2 diabetes, recognizing that cost can be a significant barrier to consistent treatment. For more information on these programs, patients can visit the Ozempic® Savings Card | Ozempic® (semaglutide) injection page directly. This direct access to manufacturer-provided savings can make a considerable difference in the overall affordability of Ozempic®.

Frequently Asked Questions

Will Medicare Part D cover GLP-1 medications in 2026?

The research provided does not explicitly state whether Medicare Part D will cover GLP-1 medications for weight loss in 2026. However, it notes that insurance is rarely accepted when a medication is used for weight loss, though "some of that is changing." For type 2 diabetes, medications like Ozempic® are typically covered. Patients should contact their Medicare Part D plan directly to confirm specific coverage for their prescribed GLP-1 medication and its intended use.

What is the average out-of-pocket cost for Wegovy® without insurance?

Without insurance, the estimated average out-of-pocket cost for Wegovy® can vary significantly. Through NovoNordisk’s NovoCare Pharmacy, the cash-pay price for the Wegovy® injection pen typically ranges from $199 to $349 per month. The new Wegovy® pill, approved in late 2025, has an estimated cash price of $149 to $299 per month for uninsured patients. These prices are much lower than the list price of $1,350 per month.

Are there any manufacturer savings programs for GLP-1 drugs?

Yes, manufacturers offer savings programs for GLP-1 drugs. For Wegovy®, NovoNordisk has launched lower-cost subscription plans and offers a savings program that can reduce costs for eligible patients. For Ozempic®, commercially covered patients can pay as little as $25 for up to a 3-month prescription. New uninsured and self-pay Ozempic® patients can pay $25 per month for the first two months of the 0.25 mg or 0.5 mg dose as a limited-time offer.

What are the serious side effects of taking Wegovy®?

Wegovy® may cause several serious side effects. These include possible thyroid tumors, including cancer, as seen in rodent studies. Other serious side effects are inflammation of the pancreas (pancreatitis) and gallbladder problems, including gallstones. Patients should also be aware of potential serious allergic reactions. It is crucial to discuss any existing medical conditions and all other medications with a healthcare provider before starting Wegovy®.

How does prior authorization impact access to GLP-1 medications?

Prior authorization significantly impacts access to GLP-1 medications by requiring insurance company approval before a prescription can be filled. This process often demands extensive documentation from healthcare providers, leading to potential delays or denials in treatment. Challenges include varying criteria across insurance plans and the administrative burden on clinics. However, solutions like electronic prior authorization (ePA) systems and platforms such as CoverMyMeds are available to help simplify and streamline this process.